RemeGen's Cash Coffers Need Filling Up
Hailed as the first Chinese company to launch a homegrown antibody drug conjugate (ADC), RemeGen has recently been battling a ...
Morningstar6d
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2 ...
Profitable Klarna files for a potentially blockbuster IPO
Swedish fintech Klarna took the next step in its highly anticipated U.S. IPO on Friday when it made its F-1 public. Here are ...
U.S. IPO Weekly Recap: One Micro-Cap Lists, While Klarna And Hinge Health's IPO Filings Boosts Pipeline
Home improvement products distributor Marwynn priced its IPO at the bottom of the range to raise $8 million at a $68 million ...
pharmaphorum2d
Kelun's MSD-partnered TROP2 drug gets first okay in China
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).